Extended Data Fig. 7: Pre-treatment strategy using vivo-morpholino in vitro and in vivo H650 models.
From: Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
a, Morpholino oligo pre-treatment strategy. H650 cells were pre-treated with 10 μM control vivo-morpholino and target vivo-morpholino for 1 to 4 days as 3D suspension cells. After drug washout, cells were cultured in growth media and cell viability was evaluated on day 8 in vitro. Luciferase-expressing H650 cells were used for in vivo experiments. After pre-treatment with 10 μM vivoMor-CTRL and target vivo-morpholino for 1 to 2 days as 3D suspension cells, drugs were washed out and cells were subcutaneously implanted into mice. In vivo imaging was performed twice a week. b, In vitro cell viability assays of H650 cells pre-treated with 10μM vivoMor-CTRL or vivoMor-4 for 1 to 4 days (n = 6 biological replicates, mean ± s.d., t test, **p < 0.01). c, Volume change of pre-treated H650 xenograft tumors. H650 cells were pre-treated with vivoMor-CTRL or vivoMor-4 in vitro for 1 or 2 days prior to injection into nude mice (n = 10 per each group, mean ± s.e.m., t-test and linear mixed growth models at day 22, **p < 0.01).
